Teva launches 1% sodium hyaluronate in U.S.

Teva Pharmaceutical Industries (NYSE:TEVA) commences the U.S. commercial launch of 1% sodium hyaluronate for the treatment of pain associated with osteoarthritis of the knee in patients who have failed to adequately respond to non-drug therapy and simple painkillers (e.g., acetaminophen).

https://seekingalpha.com/news/3474888-teva-launches-1-percent-sodium-hyaluronate-u-s